Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A group of prominent scientists, including Daniel Ebner from the TDI, shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines.